Stockscreener 앱 받기
43.96
3.26%
-1.48
전일 마감가:
$45.44
열려 있는:
$45.44
하루 거래량:
2.79M
Relative Volume:
1.01
시가총액:
$11.79B
수익:
$2.17B
순이익/손실:
$521.27M
주가수익비율:
24.84
EPS:
1.77
순현금흐름:
$633.79M
1주 성능:
-0.18%
1개월 성능:
+5.67%
6개월 성능:
-1.90%
1년 성능:
+20.27%
1일 변동 폭
$43.54
$45.52
1주일 범위
$42.05
$45.77
52주 변동 폭
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
43.96 | 12.18B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-11-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 개시 | Goldman | Buy |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis, Inc. $EXEL Shares Sold by Nisa Investment Advisors LLC - MarketBeat
Exelixis, Inc. $EXEL Shares Sold by EULAV Asset Management - MarketBeat
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - sharewise.com
Truist Financial Sticks to Their Buy Rating for Exelixis (EXEL) - The Globe and Mail
Exelixis, Inc. (EXEL): A Bull Case Theory - Finviz
Growth Recap: Is Exelixis Inc a play on infrastructure spendingM&A Rumor & Weekly High Momentum Picks - baoquankhu1.vn
EXELIXIS INC (NASDAQ:EXEL) Presents a High-Growth Momentum and Technical Breakout Opportunity - Chartmill
Meritage Portfolio Management Has $12.20 Million Stock Position in Exelixis, Inc. $EXEL - MarketBeat
InSilico Lands Drug Discovery Deal After Hong Kong IPO - Benzinga
Does Exelixis’ 2026 Revenue Guidance and Zanzalintinib Push Change The Bull Case For EXEL? - Sahm
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Finviz
Truist Securities raises Exelixis stock price target to $51 on oncology growth - Investing.com Canada
Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating - marketscreener.com
Exelixis, Inc. $EXEL Shares Sold by New York State Teachers Retirement System - MarketBeat
Citizens reiterates Market Outperform rating on Exelixis stock By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Exelixis Posts Preliminary '25 Results, Issues '26 Outlook - sharewise.com
EXEL: Franchise-focused oncology growth, strong 2025 results, and robust 2026 outlook driven by innovation - TradingView — Track All Markets
EXEL: Disciplined franchise strategy and strong pipeline drive growth in oncology markets - TradingView — Track All Markets
Exelixis cut to underperform at BofA on valuation and lack of catalysts - MSN
Lobbying Update: $30,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative
Exelixis (NASDAQ:EXEL) Shares Gap DownShould You Sell? - MarketBeat
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results and 2026 Guidance - TradingView — Track All Markets
Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Exelixis, Inc. (EXEL) Stock Analysis: Exploring The 3.32% Potential Upside - DirectorsTalk Interviews
Exelixis (EXEL) Sets Ambitious Plans in Oncology Sector - GuruFocus
Exelixis says fiscal year 2026 net product revenues guidance of $2.325 billion$2.425 billion - marketscreener.com
Exelixis Says Fiscal Year 2026 Net Product Revenues Guidance Of $2.325 Billion$2.425 Billion - TradingView — Track All Markets
Daily News - FinancialContent
Technical Reactions to EXEL Trends in Macro Strategies - Stock Traders Daily
Exelixis Provides 2026 Financial Guidance: Anticipates $2.525B to $2.625B in Revenue - Intellectia AI
EXELIXIS Q4 2025 Earnings Preview: Recent $EXEL Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
CapEx per share of Exelixis, Inc. – FWB:EX9 - TradingView — Track All Markets
Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer - MSN
Moran Wealth Management LLC Sells 23,495 Shares of Exelixis, Inc. $EXEL - MarketBeat
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story - Yahoo Finance
Assessing Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And STELLAR-316 Trial Plans - Yahoo Finance
Exelixis, Inc.Common Stock (NQ: EXEL - FinancialContent
EXELExelixis Announces Third Quarter 2009 Financial Results - ADVFN
EXEL: HC Wainwright Raises Price Target and Maintains Buy Rating - GuruFocus
How risky is Exelixis Inc. stock nowRate Cut & Smart Swing Trading Techniques - ulpravda.ru
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study - Finviz
EXEL Receives Downgrade from Morgan Stanley, Price Target Increa - GuruFocus
What is the fair value of Exelixis Inc. stock nowMarket Trend Report & Risk Controlled Daily Plans - ulpravda.ru
Morgan Stanley Reiterates "Equal Weight" Rating for Exelixis (NASDAQ:EXEL) - MarketBeat
Is It Time To Reassess Exelixis (EXEL) After Strong Multi‑Year Share Price Gains - Yahoo Finance
What 10 Analyst Ratings Have To Say About Exelixis - Benzinga
Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48 - marketscreener.com
EXEL FinancialsIncome Statement - Quiver Quantitative
2 Healthcare Stocks to Buy for 2026 and Beyond - Finviz
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):